Method Development and Validation for Estimation of Bedaquiline and in Tablet Dosage form by Hptlc and Rp-Hplc Study

Method Development and Validation for Estimation of Bedaquiline and in Tablet Dosage form by Hptlc and Rp-Hplc Study J Chandrudu Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies(VISTAS), Pallavaram, Chennai-600117, Tamil Nadu, India. https://orcid.org/0000-0001-5427-4021 Gandhimathi R Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies(VISTAS), Pallavaram, Chennai-600117, Tamil Nadu, India. https://orcid.org/0000-0002-0595-8766

A diarylquinoline anti-mycobacterial drug, bedaquiline (BDQ), treats mycobacterial infections. It inhibits the proton pump by inhibiting mycobacterial Adenosine Triphosphate (ATP) synthase. ATP enzyme that is energy production requires Mycobacterium tuberculosis. The present study aimed to develop three analytical methods, i.e., High-performance thin-layer chromatography (HPTLC), HPLC, and UV, as BDQ estimation in tablet forms. HPTLC is employed in the first method, which uses ethanol-chloroform-toluene as the mobile phase (6:3.5:0.5). UV spectroscopy at 240nm was used to analyse BDQ at 100-300 micrograms per milliliter. RP-HPLC method based on the separation using a C18 column, Buffer (sodium acetate): Methyl alcohol (70:30) as mobile phase flowing at a rate of 1ml per min. The retention time was determined to be 5.4 minutes. At 240 nm, it could quantify the concentrations of 5-25 g per ml at concentrations of 5-20 g per ml. The third method involves the "UV-VISIBLE” spectrophotometric method. A range of BDQ concentrations is determined of 8-40µg/ml, respectively. These methods were checked to ICH guidelines, and as a result, a commercially available pharmaceutical formulation, with the findings of statistical comparison, was conducted between all three methods.
3 20 2024 3 20 2024 299 307 10.13005/bpj/cm_policy 2024-3-20 http://creativecommons.org/licenses/by/4.0/ 10.13005/bpj/2858 https://biomedpharmajournal.org/vol17no1/method-development-and-validation-for-estimation-of-bedaquiline-and-in-tablet-dosage-form-by-hptlc-and-rp-hplc-study/ https://biomedpharmajournal.org/vol17no1/method-development-and-validation-for-estimation-of-bedaquiline-and-in-tablet-dosage-form-by-hptlc-and-rp-hplc-study/ 10.7860/jcdr/2016/19052.8286 1. Yadav S, Rawal G, Baxi M. Bedaquiline. A novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. J Clin Diagn Res. 2016; 10:FM01–FM02. 10.1001/jama.1995.03520270054031 2. Raviglione MC, Kochi A, Snider DE. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995; 273:220–226. 10.4046/trd.2016.79.4.201 3. Lee SH. Tuberculosis infection and latent tuberculosis. Tuberc Respir Dis (Seoul). 2016;79:201–206. 10.12816/0005977 4. Nazir T, Abraham S, Islam A. Emergence of potential superbug Mycobacterium tuberculosis, lessons from New Delhi mutant-1 bacterial strains. Int J Health Sci (Qassim). 2012; 6:87–94. 10.1016/j.jpba.2019.07.023 5. Gray WA, Waldorf B, Rao MG, et al. Development and validation of an LCMS/MS method for the simultaneous determination of Bedaquiline and Rifabutin in human plasma. J. Pharm. Biomed. Anal. 2019; 176:112775. 10.1128/aac.00276-15 6. Alffenaar JWC, Bolhuis M, Van Hateren K, et al. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. AAC., 2018; 59:5675– 5680. 10.3724/sp.j.1123.2011.00346 7. Hui Z, Zhong-Quan L, Li X, Shao-Chen G, et al. Determination of Bedaquiline plasma concentration by high-performance liquid chromatography-mass spectrometry/mass spectrometry. Chinese Journal of Antituberculosis. 2018; 40:1319. 10.1093/chromsci/bmw050 8. Dousa M, Reitmajer J, Lustig P, Stefko M. Effect of chromatographic conditions on Enantio-separation of Bedaquiline using polysaccharide-based chiral stationary phases in RP-HPLC. J. Chromatogr. Sci. 2016; 54:1501–1507. 10.1002/chir.23037 9. Jiang S, Wu C, Yu J, Sun T, Guo X. Separating eight bedaquiline analog diastereomers by HPLC on an immobilized polysaccharide-based chiral stationary phase; Chirality. 2019; 31:72–78. 10.22541/au.161148453.30803063/v1 10. Gone V, Thakur S, Akoju Y, et al. Pharmacokinetic study of bedaquiline among Indian mdr-tb patients in a clinical setting. Author. 2021; 24:34-40. 10.1186/s43094-021-00235-1 11. Rajput SJ, Vanavi PJ. Evaluation of physicochemical stability and degradation kinetics of bedaquiline in hydrolytic solutions of different pH. Future J. Pharm. Sci. 2021; 88. 10.22159/ijpps.2021v13i6.40853 12. Kumar AKH, Sudha V, Vijaya Kumar A, Padmapriyadarsini C. Simultaneous method for estimating bedaquiline and delamanid in human plasma using high-performance liquid chromatography. Int. J. Pharm. Pharm. Sci. 2021; 13:36– 40. 13. Pooja BS, Shetty SS. Develop and validate UV spectrophotometric methods for estimating bedaquiline in bulk and pharmaceutical formulations. World. J. Pharm. Res. 2018; 7:1579–1586. 10.1080/10826076.2018.1437748 14. Momin MA, Rangnekar B, Das SC. Development and validation of an RP-HPLC method for simultaneous quantification of bedaquiline (TMC 207), moxifloxacin, and pyrazinamide in a pharmaceutical powder formulation for inhalation; J. Liq. Chromatogr. Relat. Technol. 2018; 41:415–421. 15. ICH Harmonized Tripartite Guideline, ICH Q2 (R1) Text & Methodology; November 2007. 10.47583/gjfpas.2020.v01i06.001 16. ICH Harmonized Tripartite Guideline, ICH Q2 (R1)/Q14 EWG Analytical procedure development and Revision of Q2 (R1) Analytical; November